Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;30(5):1097-1154.
doi: 10.1038/s41418-023-01153-w. Epub 2023 Apr 26.

Apoptotic cell death in disease-Current understanding of the NCCD 2023

Ilio Vitale  1   2 Federico Pietrocola  3 Emma Guilbaud  4 Stuart A Aaronson  5 John M Abrams  6 Dieter Adam  7 Massimiliano Agostini  8 Patrizia Agostinis  9   10 Emad S Alnemri  11 Lucia Altucci  12   13 Ivano Amelio  14 David W Andrews  15   16 Rami I Aqeilan  17 Eli Arama  18 Eric H Baehrecke  19 Siddharth Balachandran  20 Daniele Bano  21 Nickolai A Barlev  22 Jiri Bartek  23   24 Nicolas G Bazan  25 Christoph Becker  26 Francesca Bernassola  8 Mathieu J M Bertrand  27   28 Marco E Bianchi  29 Mikhail V Blagosklonny  30 J Magarian Blander  31   32   33 Giovanni Blandino  34 Klas Blomgren  35   36 Christoph Borner  37 Carl D Bortner  38 Pierluigi Bove  8 Patricia Boya  39 Catherine Brenner  40 Petr Broz  41 Thomas Brunner  42 Rune Busk Damgaard  43 George A Calin  44   45 Michelangelo Campanella  46   47   48 Eleonora Candi  8 Michele Carbone  49 Didac Carmona-Gutierrez  50 Francesco Cecconi  51   52   53 Francis K-M Chan  54 Guo-Qiang Chen  55 Quan Chen  56 Youhai H Chen  57 Emily H Cheng  58 Jerry E Chipuk  59 John A Cidlowski  38 Aaron Ciechanover  60 Gennaro Ciliberto  34 Marcus Conrad  61 Juan R Cubillos-Ruiz  62 Peter E Czabotar  63   64 Vincenzo D'Angiolella  65 Mads Daugaard  66 Ted M Dawson  67 Valina L Dawson  67 Ruggero De Maria  52   53 Bart De Strooper  68   69   70   71 Klaus-Michael Debatin  72 Ralph J Deberardinis  73 Alexei Degterev  74 Giannino Del Sal  75   76   77 Mohanish Deshmukh  78 Francesco Di Virgilio  79 Marc Diederich  80 Scott J Dixon  81 Brian D Dynlacht  82 Wafik S El-Deiry  83   84   85 John W Elrod  86 Kurt Engeland  87 Gian Maria Fimia  88   89 Claudia Galassi  4 Carlo Ganini  8   90 Ana J Garcia-Saez  91 Abhishek D Garg  9 Carmen Garrido  92   93   94 Evripidis Gavathiotis  95   96   97   98   99 Motti Gerlic  100 Sourav Ghosh  101 Douglas R Green  102 Lloyd A Greene  103 Hinrich Gronemeyer  104   105   106   107 Georg Häcker  108   109 György Hajnóczky  110 J Marie Hardwick  111   112 Ygal Haupt  113   114 Sudan He  115   116 David M Heery  117 Michael O Hengartner  118 Claudio Hetz  119   120   121   122 David A Hildeman  123 Hidenori Ichijo  124 Satoshi Inoue  125 Marja Jäättelä  126   127 Ana Janic  128 Bertrand Joseph  129 Philipp J Jost  130 Thirumala-Devi Kanneganti  102 Michael Karin  131 Hamid Kashkar  132 Thomas Kaufmann  133 Gemma L Kelly  63   64 Oliver Kepp  134   135 Adi Kimchi  18 Richard N Kitsis  95   96   97   98   136   137 Daniel J Klionsky  138 Ruth Kluck  63   64 Dmitri V Krysko  139   140 Dagmar Kulms  141   142 Sharad Kumar  143   144 Sergio Lavandero  145   146 Inna N Lavrik  147 John J Lemasters  148 Gianmaria Liccardi  149 Andreas Linkermann  150   151 Stuart A Lipton  152   153   154 Richard A Lockshin  155   156 Carlos López-Otín  157 Tom Luedde  158 Marion MacFarlane  159 Frank Madeo  50   160   161 Walter Malorni  162 Gwenola Manic  163   164 Roberto Mantovani  165 Saverio Marchi  166 Jean-Christophe Marine  10   167 Seamus J Martin  168 Jean-Claude Martinou  169 Pier G Mastroberardino  170   171   172 Jan Paul Medema  173   174 Patrick Mehlen  175 Pascal Meier  176 Gerry Melino  8 Sonia Melino  177 Edward A Miao  54 Ute M Moll  178 Cristina Muñoz-Pinedo  179 Daniel J Murphy  180   181 Maria Victoria Niklison-Chirou  182 Flavia Novelli  49 Gabriel Núñez  183 Andrew Oberst  184 Dimitry Ofengeim  185 Joseph T Opferman  186 Moshe Oren  187 Michele Pagano  188 Theocharis Panaretakis  129   189 Manolis Pasparakis  91 Josef M Penninger  190   191 Francesca Pentimalli  192 David M Pereira  193 Shazib Pervaiz  194   195   196   197 Marcus E Peter  198 Paolo Pinton  79 Giovanni Porta  199 Jochen H M Prehn  200 Hamsa Puthalakath  201 Gabriel A Rabinovich  202 Krishnaraj Rajalingam  203 Kodi S Ravichandran  27   204   205 Markus Rehm  206 Jean-Ehrland Ricci  207 Rosario Rizzuto  208 Nirmal Robinson  143 Cecilia M P Rodrigues  209 Barak Rotblat  210   211 Carla V Rothlin  212 David C Rubinsztein  213   214 Thomas Rudel  215 Alessandro Rufini  165   216 Kevin M Ryan  180   181 Kristopher A Sarosiek  217   218   219 Akira Sawa  220 Emre Sayan  221 Kate Schroder  222 Luca Scorrano  223   224 Federico Sesti  225 Feng Shao  226 Yufang Shi  8   227   228 Giuseppe S Sica  229 John Silke  63   64 Hans-Uwe Simon  133   230 Antonella Sistigu  231 Anastasis Stephanou  232 Brent R Stockwell  233 Flavie Strapazzon  234   235 Andreas Strasser  63   64 Liming Sun  236 Erwei Sun  237 Qiang Sun  238   239 Gyorgy Szabadkai  208   240 Stephen W G Tait  180   181 Daolin Tang  241 Nektarios Tavernarakis  242   243 Carol M Troy  244 Boris Turk  245   246 Nicoletta Urbano  247 Peter Vandenabeele  27   28   248 Tom Vanden Berghe  27   28   249 Matthew G Vander Heiden  250   251   252 Jacqueline L Vanderluit  253 Alexei Verkhratsky  254   255   256   257 Andreas Villunger  258   259   260 Silvia von Karstedt  261   262   263 Anne K Voss  63   64 Karen H Vousden  70 Domagoj Vucic  264 Daniela Vuri  8 Erwin F Wagner  265   266 Henning Walczak  149   262   267 David Wallach  268 Ruoning Wang  269 Ying Wang  270 Achim Weber  271   272 Will Wood  273 Takahiro Yamazaki  4 Huang-Tian Yang  270 Zahra Zakeri  274 Joanna E Zawacka-Pankau  275   276 Lin Zhang  277 Haibing Zhang  278 Boris Zhivotovsky  129   279 Wenzhao Zhou  238   239 Mauro Piacentini  48   280 Guido Kroemer  134   135   281 Lorenzo Galluzzi  282   283   284
Affiliations
Review

Apoptotic cell death in disease-Current understanding of the NCCD 2023

Ilio Vitale et al. Cell Death Differ. 2023 May.

Abstract

Apoptosis is a form of regulated cell death (RCD) that involves proteases of the caspase family. Pharmacological and genetic strategies that experimentally inhibit or delay apoptosis in mammalian systems have elucidated the key contribution of this process not only to (post-)embryonic development and adult tissue homeostasis, but also to the etiology of multiple human disorders. Consistent with this notion, while defects in the molecular machinery for apoptotic cell death impair organismal development and promote oncogenesis, the unwarranted activation of apoptosis promotes cell loss and tissue damage in the context of various neurological, cardiovascular, renal, hepatic, infectious, neoplastic and inflammatory conditions. Here, the Nomenclature Committee on Cell Death (NCCD) gathered to critically summarize an abundant pre-clinical literature mechanistically linking the core apoptotic apparatus to organismal homeostasis in the context of disease.

PubMed Disclaimer

Conflict of interest statement

All Editorial Board Members of Cell Death Differentiation, Cell Death Disease, or Cell Death Discovery are included among the authors. A. Degterev is shareholder in Denali Therapeutics. A. D. Garg has received renumeration, honorarium or consultancy fees from Boehringer Ingelheim, Miltenyi Biotec or IsoPlexis. A. Strasser and P. E. Czabotar (PEC) are employees of the Walter and Eliza Hall Institute, which has an agreement with Genentech and AbbVie and receives milestone and royalty payments related to venetoclax. Employees of the Walter and Eliza Hall Institute may be eligible for financial benefits related to these payments. PEC receives such a financial benefit as a result of previous research related to venetoclax. B. De Strooper (BDS) has no COI with the content of this paper. Possible perceived COI: BDS is or has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie and other companies. BDS is also a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna therapeutics. B. R. Stockwell is an inventor on patents and patent applications involving small molecule drug discovery, ferroptosis, and the antibody 3F3-FMA; co-founded and serves as a consultant to Exarta Therapeutics, and ProJenX Inc.; holds equity in Sonata Therapeutics, and serves as a consultant to Weatherwax Biotechnologies Corporation and Akin Gump Strauss Hauer & Feld LLP, and receives research funding from Sumitomo Dainippon Pharma Oncology. C. M. Troy has the following patent applications US20200164026, US20190142915, US20150165061, US20140024597. US2020058683, WO2018013519, WO/2020/223212. D. C. Rubinsztein serves as a consultant for Alladdin Healthcare Technologies Ltd., Mindrank AI, Nido Biosciences, Drishti Discoveries and PAQ Therapeutics. D. J. Murphy receives funding from the Merck Group (Darmstadt, Germany) & Puma Biotechnology (Los Angeles, CA, USA). D. Ofengeim is employed at SANOFI. JTO serves as a consultant for Anji Pharmaceuticals. J. T. Opferman receives research funding from AbbVie. D. W. Andrews receives funding for research in apoptosis from Amylyx. F Di Virgilio is Member of the Scientific Advisory Board (SAB) of Biosceptre Ltd (UK), and a consultant with Axxam SpA (Italy). F. Madeo has financial interest in TLL, The Longevity Labs and Samsara Therapeutics. P. Mehlen is founder and shareholder of NETRIS Pharma. G. A. Calin is the scientific founder of Ithax Pharmaceuticals. G. L. Kelly (GLK) is an employee of the Walter and Eliza Hall Institute which receives milestone and royalty payments related to venetoclax. GLK has received research funding from Servier. J. R. Cubillos-Ruiz is a scientific consultant for NextRNA Therapeutics, Inc. and Autoimmunity Biologic Solutions, Inc. K. Rajalingam is a founder and MD of KH Biotec GmbH. CVR is a scientific founder and member of the Scientific Advisory Board (SAB) of Surface Oncology, a member of Janssen Immunology SAB, and a consultant for the Roche Immunology Incubator. C. V. Rothlin has received grant support from Mirati Therapeutics. K. Schroder is a co-inventor on patent applications for NLRP3 inhibitors which have been licensed to Inflazome Ltd, a company headquartered in Dublin, Ireland. Inflazome is developing drugs that target the NLRP3 inflammasome to address unmet clinical needs in inflammatory disease. K. Schroder served on the Scientific Advisory Board of Inflazome in 2016–2017, and serves as a consultant to Quench Bio, USA and Novartis, Switzerland. L. Altucci receives funding for research from Merck and has shares in Epic SRL and CIRCE SRL. B. Joseph is cofounder of CERVO Therapeutics AB. M. Carbone received donations from the UH Foundation through donations from: the Riviera United-4-a Cure, the Melohn Family Endowment, the Honeywell International Inc., the Germaine Hope Brennan Foundation, and the Maurice and Joanna Sullivan Family Foundation. M. Carbone has a patent issued for BAP1. M. Carbone and two patents issued for HMGB1. M. Carbone is a board-certified pathologist who provides consultation for pleural pathology, including medical-legal. M. Conrad is a co-founder and shareholder of ROSCUE Therapeutics GmbH. M. Karin received support from Jansen Pharmaceuticals, Merck and Gossamer Bioscience. M. Karin is founder and member of SAB, Elgia Pharmaceuticals. M. Pagano is a scientific cofounder of SEED Therapeutics; receives research funding from and is a shareholder in Kymera Therapeutics; and is a consultant for, a member of the scientific advisory board of, and has financial interests in CullGen, SEED Therapeutics, Triana Biomedicines, and Umbra Therapeutics. M. G. Vander Heiden is a scientific advisor for Agios Pharmaceuticals, iTeos Therapeutics, Sage Therapeutics, Droia Ventures, and Auron Therapeutics. M. Oren is a consultant for Quintrigen. O. Kepp is a co-founder of Samsara Therapeutics. P. J. Jost has had a consulting or advisory role, received honoraria, research funding, and/or travel/accommodation expenses from: Ariad, Abbvie, Bayer, Boehringer, Novartis, Pfizer, Servier, Roche, BMS and Celgene, Pierre Fabre, Janssen/Johnson&Johnson, MSD. R. B. Damgaard is a scientific advisor for Immagene B.V., Amsterdam, Netherlands. R. I. Aqeilan serves as consultant for Mahzi Therapeutics. R. J. DeBerardinis is a founder and advisor at Atavistik Bio and serves on the Scientific Advisory Boards of Agios Pharmaceuticals, Vida Ventures, Droia Ventures and Nirogy Therapeutics. R. N. Ktsis is Co-founder of ASPIDA Therapeutics Inc. S. A. Lipton (SAL) discloses that he is the named inventor on worldwide patents for the use of memantine and derivatives for the treatment of neurodegenerative disorders. As per the rules of Harvard University, SAL participates in a Royalty Sharing Agreement with is former institutions, Boston Children’s Hospital/Harvard Medical School, which licensed these patents to Forest Laboratories and Allergan, now owned by Abbvie. SAL is also a founder of EuMentis Therapeutics, Inc., Adamas Pharmaceuticals, Inc. (now owned by Supernus Pharmaceuticals, Inc.), and a consultant to SNO bio, Inc., Engine Biosciences, Ventus Therapeutics, Inc., Eisai, inc., and Takeda Pharmaceuticals, Inc. S. Ghosh has received grant support from Mirati Therapeutics. S. J. Dixon is a co-founder of Prothegen Inc., and a scientific advisor to Ferro Therapeutics and Hillstream BioPharma. S. von Karstedt is named inventor on patent applications covering some of the therapeutic concepts pertaining to TRAIL-R blockade in disease. Y. H. Chen is a member of the board of advisors for Amshenn Inc. and Binde Inc. T.-D. Kanneganti is a consultant for Pfizer. T. Vanden Berghe and P. Vandenabeele hold patents related to ferrostatin-1 analogues. D. R. Green consults for Ventus Therapeutics, Inzen Therapeutics, and Horizon Therapeutics. K. H. Vousden is on the board of directors and shareholder of Bristol Myers Squibb and on the scientific advisory board (with stock options) of PMV Pharma, RAZE Therapeutics, Volastra Pharmaceuticals and Kovina Therapeutics. She is on the scientific advisory board of Ludwig Cancer and a co-founder and consultant of Faeth Therapeutics. She has been in receipt of research funding from Astex Pharmaceuticals and AstraZeneca and contributed to CRUK Cancer Research Technology filing of patent application WO/2017/144877. W. S. El-Deiry (WSE-D) is founder and shareholder (no research funding) of Oncoceutics/Chimerix, which is developing ONC201/TIC10 as cancer therapeutic. WSE-D is founder and shareholder (no research funding) of p53-Therapeutics, an early-stage company developing small molecules targeting mutant p53. WSE-D founder, and shareholder (no research funding) of SMURF-Therapeutics, an early-stage company developing small molecules targeting hypoxia. WSE-D is Co-Chair in the Executive Committee for Precision Oncology Alliance (no research funding) of Caris Life Sciences. WSE-D receives support from D&D Pharma and AACR-Novocure. WSE-D is the advisory board of Ocean Biomedical. WSE-D is the advisory board of RAIN Therapeutics. G. Kroemer has been holding research contra.cts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys, and Vascage. G. Kroemer has been consulting for Reithera. G. Kroemer is on the Board of Directors of the Bristol Myers Squibb Foundation France. G. Kroemer is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. G. Kroemer is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. G. Kroemer’s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. L. Galluzzi is/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. All other authors have no conflicts to declare.

Figures

Fig. 1
Fig. 1. Principal causes of the therapeutic failure of intrinsic or extrinsic apoptosis inhibitors.
The clinical development and success of agents inhibiting apoptosis is limited by multiple contributory causes, including potential non-apoptotic, accessory or even protective roles of the targeted proteins (exemplified by the involvement of certain BCL2 family members, caspases and death receptors in processes as diverse as inflammation, cell differentiation, cell proliferation and cell survival), the high interconnectivity between RCD pathway (potentially leading to the activation of compensatory RCD variants in response to the inhibition of a specific RCD type), the low specificity and selectivity of the inhibitors developed so far (exemplified by the broad-spectrum caspase inhibitors) and the difficulty to precisely determine and quantify cell death in vivo. RCD regulated cell death.
Fig. 2
Fig. 2. Molecular machinery of the intrinsic apoptosis.
Intrinsic apoptosis can be activated by a range of extracellular or intracellular stimuli, including, but not limited to, DNA damage, endoplasmic reticulum (ER) or oxidative stress, growth factor withdrawal or microtubular alterations. The critical step of the intrinsic apoptosis is the activation of the pro-apoptotic effectors of the BCL2 family, BAX, BAK and possibly BOK, which drives the outer membrane permeabilization (MOMP) and commits cells to death. MOMP results in the release from the mitochondrial intermembrane space into the cytosol of proapoptotic proteins, including CYCS and SMAC. CYCS assembles with APAF1, dATP and pro-CASP9 into the apoptosome, leading to the activation of CASP9, which in turn promotes the activation of the executioner caspases CASP3 and CASP7. The activation of the executioner caspases is facilitated by SMAC, which sequesters and/or degrades members of IAP family that inhibit apoptosis.
Fig. 3
Fig. 3. Impact of intrinsic apoptosis players on neurological disorders.
Intrinsic apoptosis is directly or indirectly involved in the pathogenesis of multiple neurological disorders, including neurodegenerative diseases, brain damage caused by traumatic injury or neurotoxicity as well as neuromuscular and retinal disorders.
Fig. 4
Fig. 4. Molecular machinery of the extrinsic apoptosis pathway.
Extrinsic apoptosis is initiated by the binding of FASL to FAS or TRAIL to TRAIL-R1 or TRAIL-R2, which promotes the assembly, on the cytoplasmic tail of these death receptors, of a platform known as the DISC. Extrinsic apoptosis is also triggered by the binding of TNF to TNF-R1, which promotes the assembly of the Complex II. The DISC comprises FADD, c-FLIPs and pro-CASP8. Complex II is a platform consisting of FADD and pro-CASP8 in association with either TRADD (complex IIa) or RIPK1 (complex IIb). The assembly of these complexes promotes the activation of CASP8, which mediates CASP3 and CASP7 activation either directly, by catalyzing the proteolytic activation of CASP3 and CASP7 (in type I cells) or indirectly, via the proteolytic activation of the BH3-only protein BID and outer membrane permeabilization (MOMP) (in type II cells). At least in some cells, extrinsic apoptosis can also be induced by dependence receptors like DCC, NTRK3, PTCH1, or UNC5A-D, which are activated by decreased concentration of the related ligand, as illustrated in the figure. However, the role of this pathway in normal physiology and disease is not yet established.
Fig. 5
Fig. 5. Impact of extrinsic apoptosis players on neurological disorders.
Death receptor-induced apoptosis is directly or indirectly involved in the pathogenesis of multiple neurological disorders, including neurodegenerative diseases, in brain damage due to traumatic injury or neurotoxicity as well as in neuromuscular and retinal disorders.

References

    1. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486–541. doi: 10.1038/s41418-017-0012-4. - DOI - PMC - PubMed
    1. Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266–82. doi: 10.1038/s41580-020-00324-8. - DOI - PMC - PubMed
    1. Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev. 2019;99:1765–817. doi: 10.1152/physrev.00022.2018. - DOI - PMC - PubMed
    1. Bock FJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 2020;21:85–100. doi: 10.1038/s41580-019-0173-8. - DOI - PubMed
    1. Broz P, Pelegrín P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2020;20:143–57. doi: 10.1038/s41577-019-0228-2. - DOI - PubMed

Publication types